Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

790 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of Acute Pain From Non-Low Back, Musculoskeletal Injuries : A Systematic Review and Network Meta-analysis of Randomized Trials.
Busse JW, Sadeghirad B, Oparin Y, Chen E, Goshua A, May C, Hong PJ, Agarwal A, Chang Y, Ross SA, Emary P, Florez ID, Noor ST, Yao W, Lok A, Ali SH, Craigie S, Couban R, Morgan RL, Culig K, Brar S, Akbari-Kelachayeh K, Pozdnyakov A, Shergill Y, Sivananthan L, Zihayat B, Das A, Guyatt GH. Busse JW, et al. Among authors: lok a. Ann Intern Med. 2020 Nov 3;173(9):730-738. doi: 10.7326/M19-3601. Epub 2020 Aug 18. Ann Intern Med. 2020. PMID: 32805127 Free article.
Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas.
Tessoulin B, Thomare P, Delande E, Moynard J, Gastinne T, Moreau A, Bossard C, Mahé B, Blin N, Dubruille V, Touzeau C, Boudreault JS, Perrin F, Lok A, Guillaume T, Garnier A, Peterlin P, Gallas P, Chevallier P, Moreau P, Le Gouill S. Tessoulin B, et al. Among authors: lok a. Ann Hematol. 2017 Jun;96(6):943-950. doi: 10.1007/s00277-017-2981-2. Epub 2017 Apr 3. Ann Hematol. 2017. PMID: 28374163
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
Trudel S, Tessoulin B, Jullien M, Blin N, Gastinne T, Mahé B, Dubruille V, Bonnet A, Lok A, Chevallier P, Peterlin P, Garnier A, Guillaume T, Le Bourgeois A, Le Gouill S, Moreau P, Touzeau C. Trudel S, et al. Among authors: lok a. Ann Hematol. 2019 Jun;98(6):1441-1447. doi: 10.1007/s00277-019-03649-3. Epub 2019 Mar 14. Ann Hematol. 2019. PMID: 30874851
Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study.
Lassalle A, Thomaré P, Fronteau C, Mahé B, Jubé C, Blin N, Voldoire M, Dubruille V, Tessoulin B, Touzeau C, Chauvin C, Loirat M, Lok A, Bourcier J, Lestang E, Mocquet R, Barbarot V, Moreau P. Lassalle A, et al. Among authors: lok a. Ann Oncol. 2016 Feb;27(2):314-8. doi: 10.1093/annonc/mdv563. Epub 2015 Nov 16. Ann Oncol. 2016. PMID: 26578729 Free article.
Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.
Lok A, Mocquard J, Bourcier J, Redelsperger L, Bonnet A, Chauvin C, Thomaré P, Mahé B, Touzeau C, Moreau P. Lok A, et al. Haematologica. 2014 Mar;99(3):e33-4. doi: 10.3324/haematol.2013.100396. Epub 2014 Feb 14. Haematologica. 2014. PMID: 24532044 Free PMC article. No abstract available.
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Jullien M, Trudel S, Tessoulin B, Mahé B, Dubruille V, Blin N, Gastinne T, Bonnet A, Lok A, Lebourgeois A, Peterlin P, Garnier A, Chevalier P, Guillaume T, Thomaré P, Le Gouill S, Moreau P, Touzeau C. Jullien M, et al. Among authors: lok a. Ann Hematol. 2019 Jun;98(6):1435-1440. doi: 10.1007/s00277-019-03655-5. Epub 2019 Mar 14. Ann Hematol. 2019. PMID: 30874850
790 results